Pluristem Therapeutics, placenta-based cell therapies company, has announced the initiation of a Phase I clinical trial of PLX-PAD cells as a treatment for patients with tendon injures. The study will determine the efficacy of the cells to treat rotator cuff tears necessitating arthroscopic repair.
Pluristem has also announced that PLX-PAD cells are intended to grow the company's presence in the sports medicine and orthopedic markets.
More Articles on Sports Medicine:
Manhattan Orthopedic Care Releases NBA Injury Infographic
Drs. Robert Zura, Claude Moorman Perform Successful Surgery on Duke's Seth Curry
Methodist Willowbrook Hospital Opens Sports Medicine Center
Pluristem has also announced that PLX-PAD cells are intended to grow the company's presence in the sports medicine and orthopedic markets.
More Articles on Sports Medicine:
Manhattan Orthopedic Care Releases NBA Injury Infographic
Drs. Robert Zura, Claude Moorman Perform Successful Surgery on Duke's Seth Curry
Methodist Willowbrook Hospital Opens Sports Medicine Center